Scott Lish Sells 10,875 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 10,875 shares of Alphatec stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $21.47, for a total value of $233,486.25. Following the completion of the transaction, the chief operating officer directly owned 661,332 shares of the company’s stock, valued at $14,198,798.04. This represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Scott Lish also recently made the following trade(s):

• On Thursday, November 20th, Scott Lish sold 25,000 shares of Alphatec stock. The stock was sold at an average price of $19.80, for a total transaction of $495,000.00.

Alphatec Price Performance

NASDAQ:ATEC traded down $0.29 during mid-day trading on Tuesday, reaching $20.67. 1,429,220 shares of the company were exchanged, compared to its average volume of 2,120,693. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 43.02. The stock has a market cap of $3.07 billion, a PE ratio of -19.88 and a beta of 1.08. Alphatec Holdings, Inc. has a 12 month low of $8.69 and a 12 month high of $22.66. The company has a fifty day moving average of $17.92 and a 200 day moving average of $14.90.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. Alphatec’s revenue for the quarter was up 30.4% on a year-over-year basis. On average, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ATEC shares. Wells Fargo & Company lifted their target price on Alphatec from $14.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. Canaccord Genuity Group raised their price target on Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a report on Friday, October 31st. JPMorgan Chase & Co. began coverage on Alphatec in a report on Friday, October 24th. They set an “overweight” rating and a $19.00 price objective for the company. Barclays upped their target price on shares of Alphatec from $22.00 to $23.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, Piper Sandler reiterated an “overweight” rating and set a $25.00 price target (up previously from $20.00) on shares of Alphatec in a research report on Friday, October 31st. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.20.

Hedge Funds Weigh In On Alphatec

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Creative Planning grew its holdings in shares of Alphatec by 0.9% in the 3rd quarter. Creative Planning now owns 58,654 shares of the medical technology company’s stock valued at $853,000 after buying an additional 534 shares during the period. Valeo Financial Advisors LLC lifted its holdings in Alphatec by 2.1% during the third quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company’s stock worth $600,000 after acquiring an additional 846 shares in the last quarter. Norden Group LLC grew its stake in Alphatec by 2.6% in the third quarter. Norden Group LLC now owns 36,676 shares of the medical technology company’s stock valued at $533,000 after acquiring an additional 939 shares during the period. Arizona State Retirement System grew its stake in Alphatec by 2.8% in the third quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company’s stock valued at $503,000 after acquiring an additional 949 shares during the period. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of Alphatec by 8.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company’s stock worth $131,000 after acquiring an additional 955 shares in the last quarter. 66.35% of the stock is owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.